• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随机对照试验中系统性治疗斑块状银屑病中老年人的代表性:系统评价。

Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review.

机构信息

Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.

Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

J Am Acad Dermatol. 2020 Aug;83(2):412-424. doi: 10.1016/j.jaad.2019.07.079. Epub 2019 Jul 29.

DOI:10.1016/j.jaad.2019.07.079
PMID:31369769
Abstract

BACKGROUND

Psoriasis is frequently seen in older patients, and systemic treatment is often indicated. Randomized controlled trials (RCTs) generally maintain strict inclusion and exclusion criteria, which might lead to a disproportionally high exclusion rate of older adults.

OBJECTIVE

To determine the representation of older adults (≥65 years) in RCTs studying systemic treatment in plaque psoriasis.

METHODS

A systematic literature search was performed in PubMed/MEDLINE, Embase, and CENTRAL, including RCTs concerning systemic treatments in plaque psoriasis in the past 15 years. Direct exclusion (based on age limits) and indirect exclusion (other exclusion criteria) were assessed. Study selection and data extraction were performed by 2 independent reviewers.

RESULTS

Of 162 trials reviewed in full, 54 (33.3%) maintained an upper age limit (55-85 years). Of the remaining 108 trials, 106 reported exclusion criteria and did not use an upper age limit. However, 96 (90.6%) of these trials used exclusion criteria that might unequally affect older adults. The exclusion criteria serious concurrent infection (n = 104, 66.7%) and malignancy (n = 100, 64.1%) were most commonly mentioned in the included RCTs.

LIMITATIONS

Only published RCTs were included.

CONCLUSION

Older adults might be poorly represented in RCTs studying systemic treatment in plaque psoriasis because of a high rate of direct and indirect exclusion.

摘要

背景

银屑病在老年患者中较为常见,通常需要进行系统治疗。随机对照试验(RCT)通常严格遵守纳入和排除标准,这可能导致老年人的排除率过高。

目的

确定在研究斑块型银屑病系统治疗的 RCT 中老年人(≥65 岁)的代表性。

方法

对 PubMed/MEDLINE、Embase 和 CENTRAL 中的 RCT 进行了系统文献检索,这些 RCT 涉及过去 15 年中斑块型银屑病的系统治疗。评估了直接排除(基于年龄限制)和间接排除(其他排除标准)。研究选择和数据提取由 2 名独立审查员进行。

结果

在全面审查的 162 项试验中,54 项(33.3%)设定了上限年龄(55-85 岁)。在其余 108 项试验中,106 项报告了排除标准,但未使用上限年龄。然而,其中 96 项(90.6%)试验使用的排除标准可能会对老年人产生不平等影响。在纳入的 RCT 中,最常提到的排除标准是严重的合并感染(n=104,66.7%)和恶性肿瘤(n=100,64.1%)。

局限性

仅纳入了已发表的 RCT。

结论

由于老年人直接和间接排除率较高,他们在研究斑块型银屑病系统治疗的 RCT 中代表性可能较差。

相似文献

1
Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review.随机对照试验中系统性治疗斑块状银屑病中老年人的代表性:系统评价。
J Am Acad Dermatol. 2020 Aug;83(2):412-424. doi: 10.1016/j.jaad.2019.07.079. Epub 2019 Jul 29.
2
Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review.将老年人纳入特应性皮炎系统药物随机临床试验:系统评价。
JAMA Dermatol. 2020 Nov 1;156(11):1240-1245. doi: 10.1001/jamadermatol.2020.2940.
3
Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review.老年人银屑病系统治疗的有效性和安全性:系统评价。
JAMA Dermatol. 2020 Nov 1;156(11):1229-1239. doi: 10.1001/jamadermatol.2020.2311.
4
Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.生物类似药:对已发表和正在进行的用于慢性炎症性疾病的抗银屑病药物临床试验的系统评价
J Dtsch Dermatol Ges. 2015 Apr;13(4):294-300. doi: 10.1111/ddg.12621.
5
Interventions for nail psoriasis.指甲银屑病的干预措施。
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD007633. doi: 10.1002/14651858.CD007633.pub2.
6
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.与生物制剂和非生物制剂银屑病全身治疗相关的严重不良事件风险:不符合与符合随机对照试验条件的患者
Arch Dermatol. 2012 Apr;148(4):463-70. doi: 10.1001/archdermatol.2011.2768.
7
Evaluation of the fragility of pivotal trials used to support US Food and Drug Administration approval for plaque psoriasis.评估用于支持美国食品和药物管理局批准斑块状银屑病的关键性试验的脆弱性。
J Am Acad Dermatol. 2021 Feb;84(2):354-360. doi: 10.1016/j.jaad.2020.04.057. Epub 2020 Apr 19.
8
Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.生物制剂治疗中重度银屑病的疗效:一项随机对照试验的网络荟萃分析。
Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.
9
Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.临床实践中生物制剂的使用者:他们是否有资格参加 III 期临床试验?法国银屑病登记处 PSOBIOTEQ 的队列研究。
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):293-300. doi: 10.1111/jdv.15878. Epub 2019 Oct 17.
10
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.对13项试验进行的综合分析,总结了接受多达九个疗程治疗的银屑病患者使用阿法赛特的长期安全性。
Clin Ther. 2005 Dec;27(12):1912-21. doi: 10.1016/j.clinthera.2005.12.007.

引用本文的文献

1
Systemic Therapies for Psoriatic Disease and Serious Infections in Older Adults.老年银屑病患者的系统性治疗与严重感染
JAMA Dermatol. 2025 May 1;161(5):490-497. doi: 10.1001/jamadermatol.2025.0144.
2
Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.替西罗莫司在老年患者中的疗效和安全性:两项随机 III 期临床试验(reSURFACE 1 和 reSURFACE 2)的 244 周汇总分析。
Acta Derm Venereol. 2023 Oct 25;103:adv17752. doi: 10.2340/actadv.v103.17752.
3
Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study.
老年人银屑病常规和生物系统治疗的安全性评估:一项真实世界多中心队列研究。
Acta Derm Venereol. 2022 Oct 31;102:adv00805. doi: 10.2340/actadv.v102.2412.
4
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.生物制剂在老年银屑病患者中的生存、安全性和有效性:与年轻患者的比较——一项 BioCAPTURE 登记研究。
Drugs Aging. 2022 Sep;39(9):715-727. doi: 10.1007/s40266-022-00961-y. Epub 2022 Jul 21.
5
Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups.老年银屑病的疾病与治疗特征:一项比较年龄组的患者调查
Acta Derm Venereol. 2020 Jul 28;100(14):adv00215. doi: 10.2340/00015555-3569.